Neurologia最新文献

{"title":"Mild sensory symptoms during SARS-CoV-2 infection among healthcare professionals","authors":"D. Gayoso Cantero ,&nbsp;E. Cantador Pavón ,&nbsp;E. Pérez Fernández ,&nbsp;M.E. Novillo López","doi":"10.1016/j.nrleng.2021.06.007","DOIUrl":"10.1016/j.nrleng.2021.06.007","url":null,"abstract":"<div><h3>Introduction</h3><p>It is not yet possible to estimate the proportion of patients with COVID-19 who present distinguishable classical neurological symptoms and syndromes.</p><p>The objective of this study is to estimate the incidence of sensory symptoms (hypoaesthesia, paraesthesia, and hyperalgesia) in physicians who have presented the disease at Hospital Universitario Fundación Alcorcón (HUFA) in Madrid; to establish the relationship between sensory symptoms and the presence of other signs of infection; and to study their association with the severity of COVID-19.</p></div><div><h3>Methods</h3><p>We conducted a descriptive, cross-sectional, retrospective, observational study. HUFA physicians who presented SARS-CoV-2 infection between 1 March and 25 July 2020 were included in the study. A voluntary, anonymous survey was distributed via corporate email. Sociodemographic and clinical characteristics were collected from professionals with PCR- or serology-confirmed COVID-19.</p></div><div><h3>Results</h3><p>The survey was sent to 801 physicians and we received 89 responses. The mean age of respondents was 38.28 years. A total of 17.98% presented sensory symptoms. A significant relationship was found between the presence of paraesthesia and cough, fever, myalgia, asthaenia, and dyspnoea. A significant relationship was also found between paraesthesia and the need for treatment and admission due to COVID-19. Sensory symptoms were present from the fifth day of illness in 87.4% of cases.</p></div><div><h3>Conclusions</h3><p>SARS-CoV-2 infection can be associated with sensory symptoms, mostly in severe cases. Sensory symptoms often appear after a time interval, and may be caused by a parainfectious syndrome with an autoimmunity background.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 5","pages":"Pages 392-398"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9448445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study","authors":"J.E. Meca-Lallana ,&nbsp;J.C. Álvarez-Cermeño ,&nbsp;B. Casanova Estruch ,&nbsp;G. Izquierdo Ayuso ,&nbsp;R. Ortiz Castillo ,&nbsp;A. Rodríguez-Antigüedad ,&nbsp;C. Calles Hernández ,&nbsp;en nombre del Grupo de Estudio LEMVIDA","doi":"10.1016/j.nrleng.2021.06.006","DOIUrl":"10.1016/j.nrleng.2021.06.006","url":null,"abstract":"<div><h3>Introduction</h3><p>LEMVIDA is a real-world prospective study of 3-year follow-up on quality of life of patients with multiple sclerosis (MS) receiving alemtuzumab in Spain.</p></div><div><h3>Methods</h3><p>This is an interim analysis evaluating the baseline characteristics of patients who started alemtuzumab between October 2016-September 2018. For 3 additional subanalysis patients were categorised by baseline EDSS score; time of alemtuzumab initiation during the recruitment period (cohort 1: October 2016-March 2017, cohort 2: April-September 2017, cohort 3: October 2017-March 2018 and cohort 4: April-September 2018); and the presence of highly active MS criteria.</p></div><div><h3>Results</h3><p>161 patients were analysed: 67.1% female, age 38.7 ± 9.4 years, MS duration 8.5 ± 6.0 years, EDSS 3.3 ± 1.7 and number of relapses in the previous 2 years 1.8 ± 1.3. 48.3% of patients presented gadolinium-enhanced (Gd+) lesions (mean: 5.2 ± 6.9) and 63.1% had received prior treatment with fingolimod or natalizumab. Baseline EDSS scores and number of Gd+ lesions were higher in cohort 1 than in cohort 4 (4.1 ± 1.8 vs 3.2 ± 1.7; <em>P</em> = .040 and 10.9 ± 11.9 vs 4.5 ± 5.7; <em>P</em> = .020). The frequency of prior treatment with fingolimod and natalizumab was lower in cohort 4 (60.6%) than in cohort 1 (70.6%) (comparison between groups not analysed).</p></div><div><h3>Conclusions</h3><p>Unlike phase 3 studies of alemtuzumab, the patients included in LEMVIDA are older, have a longer duration of MS, higher disability and have received previous immunosuppressants. However, throughout the recruitment period, there is a tendency towards an early beginning of treatment with alemtuzumab, probably due to the evidence of higher effectiveness in the early stages of MS.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 5","pages":"Pages 383-391"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580823000159/pdfft?md5=9eb8f8b2e15a6b14c27cd11122c053a6&pid=1-s2.0-S2173580823000159-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9827636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palliative care management in patients with Parkinson’s disease and other movement disorders in Spain. National survey of neurologists","authors":"M. Álvarez Saúco ,&nbsp;R. García- Ramos ,&nbsp;I. Legarda Ramírez ,&nbsp;F. Carrillo García ,&nbsp;J. Fernández Bueno ,&nbsp;S. Martí Martínez ,&nbsp;B. González García ,&nbsp;A. Moya-Martínez ,&nbsp;D. Santos-García","doi":"10.1016/j.nrleng.2021.09.010","DOIUrl":"10.1016/j.nrleng.2021.09.010","url":null,"abstract":"<div><h3>Introduction</h3><p>Palliative care in neurodegenerative diseases is useful but underused. The objective of this study is to know how palliative care (PC) is applied in Spain in order to identify limitations and unmet needs.</p></div><div><h3>Materials and Methods</h3><p>It is a descriptive, observational, cross-sectional study, anonymous survey type of 20 questions, directed and answered by neurologists dedicated to movement disorders (MD) in Spain.</p></div><div><h3>Results</h3><p>58 responses were obtained from neurologists from 15 autonomous communities. 69% answered that they did not have a specialised MD nursing facility but did have a PC team in their centre (81%). No specific protocol for PC in MD was identified. All except one neurologist stated that they lacked sufficient training in PC, the main training need being the “advance directives explanation”. Only 1 in 4 neurologists answered routinely explaining advance healthcare planning to their patients, recognising up to 84.5% of neurologists not knowing how to assess the patient's competence. 60.3% of those surveyed answered that between 10% and 30% of their patients would be candidates for PC, although 1 in 3 said they were not clear when to refer the patient to PC. 100% of neurologists affirmed the priority need to implement PC protocols in MD.</p></div><div><h3>Conclusions</h3><p>Our study shows a formative deficit in PC in this area and in the care of the patient with movement disorders and their environment, and should serve as a starting point to develop consensual care protocols.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 5","pages":"Pages 417-425"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580823000196/pdfft?md5=240da4889cf7f6b3d436aa774fdb4e9b&pid=1-s2.0-S2173580823000196-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9423593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3-Acetylpyridine-induced ataxic-like motor impairments are associated with plastic changes in the Purkinje cells of the rat cerebellum","authors":"D. González-Tapia ,&nbsp;N. Vázquez-Hernández ,&nbsp;F. Urmeneta-Ortiz ,&nbsp;N. Navidad-Hernandez ,&nbsp;M. Lazo-Yepez ,&nbsp;A. Tejeda-Martínez ,&nbsp;M. Flores-Soto ,&nbsp;I. González-Burgos","doi":"10.1016/j.nrleng.2021.09.015","DOIUrl":"10.1016/j.nrleng.2021.09.015","url":null,"abstract":"<div><p>Ataxias are characterized by aberrant movement patterns closely related to cerebellar dysfunction. Purkinje cell axons are the sole outputs from the cerebellar cortex, and dysfunctional activity of Purkinje cells has been associated with ataxic movements. However, the synaptic characteristics of Purkinje cells in cases of ataxia are not yet well understood. The nicotinamide antagonist 3-acethylpyridine (3-AP) selectively destroys inferior olivary nucleus neurons so it is widely used to induce cerebellar ataxia. Five days after 3-AP treatment (65<!--> <!-->mg/kg) in adult male Sprague-Dawley rats, motor incoordination was revealed through BBB and Rotarod testing. In addition, in Purkinje cells from lobules V–VII of the cerebellar vermis studied by the Golgi method, the density of dendritic spines decreased, especially the thin and mushroom types. Western blot analysis showed a decrease in AMPA and PSD-95 content with an increase of the α-catenin protein, while GAD-67 and synaptophysin were unchanged. Findings suggest a limited capacity of Purkinje cells to acquire and consolidate afferent excitatory inputs and an aberrant, rigid profile in the movement-related output patterns of Purkinje neurons that likely contributes to the motor-related impairments characteristic of cerebellar ataxias.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 5","pages":"Pages 408-416"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000518/pdfft?md5=17232e625cc91411acb2acead865a7e9&pid=1-s2.0-S2173580824000518-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141237000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Status epilepticus—Therapeutic management at the pediatric emergency department","authors":"I. Pais-Cunha ,&nbsp;D. Valente ,&nbsp;D.B. Abreu ,&nbsp;J. Fonseca ,&nbsp;C. Melo ,&nbsp;M. Sampaio ,&nbsp;L.A. Santos ,&nbsp;R. Sousa","doi":"10.1016/j.nrleng.2021.09.014","DOIUrl":"10.1016/j.nrleng.2021.09.014","url":null,"abstract":"<div><h3>Introduction</h3><p>Status epilepticus is an important cause of pediatric neurological emergency. Immediate treatment is essential to prevent definitive neurological damage. Several antiepileptic drugs are available for the management of status epilepticus.</p></div><div><h3>Methods</h3><p>Retrospective study of patients admitted at the emergency department of a tertiary hospital for 5 years (2014–2019). We analyzed the compliance to the treatment guidelines for pediatric status epilepticus.</p></div><div><h3>Results</h3><p>One hundred and seventeen admissions were identified, 23.9% of these were febrile status epilepticus. Among the other cases, the most frequent cause was genetic (22.2%). The majority were convulsive status epilepticus (93.1%), 58.7% of which were generalized tonic–clonic seizures. Benzodiazepines were the most used first and second line drug (98.2% and 94.8%). The most frequent third drug used was diazepam (56.4%) followed by phenytoin (18.2%). An infra-therapeutic antiepileptic drug dose was given in 48.7% of cases. 49.6% presented with a prolonged status epilepticus and 6.8% needed intensive care. Incorrect sequence of drugs and infra-therapeutic doses were associated with prolonged status (<em>p</em> <!-->&lt;<!--> <!-->0.001 and <em>p</em> <!-->&lt;<!--> <!-->0.05) and an increased number of antiepileptic drugs used (<em>p</em> <!-->&lt;<!--> <!-->0.001 and <em>p</em> <!-->&lt;<!--> <!-->0.05).</p></div><div><h3>Conclusions</h3><p>Benzodiazepines were the most frequently first and second line drugs used for status epilepticus management. Surprisingly, the most frequently third line drugs used were also benzodiazepines. These findings were partially explained by the misuse of infra-therapeutic doses of these drugs. Noncompliance with the implemented guidelines was associated with unfavorable outcomes.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 5","pages":"Pages 426-431"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000506/pdfft?md5=acdf5e1cad1439da9380b7ce94341855&pid=1-s2.0-S2173580824000506-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141237647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Memory changes in patients with hippocampal sclerosis submitted to surgery to treat mesial temporal lobe epilepsy","authors":"E. Leal-Conceição ,&nbsp;M. Muxfeldt Bianchin ,&nbsp;W. Vendramini Borelli ,&nbsp;V. Spencer Escobar ,&nbsp;L. Januário de Oliveira ,&nbsp;M. Bernardes Wagner ,&nbsp;A. Palmini ,&nbsp;E. Paglioli ,&nbsp;G. Radaelli ,&nbsp;J. Costa da Costa ,&nbsp;M. Wetters Portuguez","doi":"10.1016/j.nrleng.2021.07.007","DOIUrl":"10.1016/j.nrleng.2021.07.007","url":null,"abstract":"<div><h3>Purpose</h3><p>This study was performed with the purpose of analysing the relationship between epileptological and surgical variables and post-operative memory performance, following surgery for refractory mesial temporal lobe epilepsy (MTLE) due to hippocampal sclerosis (HS).</p></div><div><h3>Methods</h3><p>Logical memory (LM) and visual memory (VM) scores for immediate and late follow-up of 201 patients operated for MTLE/HS were reviewed. Scores were standardized with a control group of 54 healthy individuals matched for age and education. The Reliable Change Index (RCI) was calculated to verify individual memory changes for late LM and VM scores. A multiple linear regression analysis was carried out with the RCI, using LM and VM scores as well as the clinical variables.</p></div><div><h3>Results</h3><p>A total of 112 (56%) patients had right HS. The RCI of the right HS group demonstrated that 6 (7%) patients showed improvement while 5 (6%) patients showed decreased scores in late LM; for late VM, 7 (8%) patients presented improvement, and 2 (3%) patients showed poorer scores. RCI of the left HS group showed that 3 (3%) individuals showed improved scores, while scores of 5 (4%) patients worsened for late LM; for late VM, 3 (3%) patients presented higher scores and 6 (5%) showed lower scores. Left HS and advanced age at onset of the first epileptic seizure were predictors of late LM loss (<em>p</em> <!-->&lt;<!--> <!-->.05).</p></div><div><h3>Conclusion</h3><p>Left MTLE/HS and seizure onset at advanced ages were predictive factors for the worsening of late LM. We observed poorer baseline LM function in the left HS group and improvement of LM in some patients who had resection of the right MTL. Patients in the right HS group showed a higher percentage of reliable post-operative improvement for both VM and LM scores.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 5","pages":"Pages 399-407"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S217358082400052X/pdfft?md5=09b95be9cc7d76ae573018f32d68e285&pid=1-s2.0-S217358082400052X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141237062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive factors of destination at discharge after spinal cord injury","authors":"E. Bárbara-Bataller ,&nbsp;J.L. Méndez-Suárez ,&nbsp;C. Alemán-Sánchez ,&nbsp;P. Peñaloza-Polo ,&nbsp;J. Sánchez-Enríquez ,&nbsp;P. Saavedra-Santana","doi":"10.1016/j.nrleng.2021.09.011","DOIUrl":"10.1016/j.nrleng.2021.09.011","url":null,"abstract":"<div><h3>Introduction</h3><p>One of the main goals of the rehabilitation of patients with spinal cord injury (SCI) is the reintegration of the individual to their family, social, and work setting. The objective of this study was to identify the factors that determine the discharge destination after a traumatic spinal cord injury.</p></div><div><h3>Material and methods</h3><p>We conducted a retrospective descriptive study of 305 patients with SCI who completed the rehabilitation treatment at the spinal injury unit of Hospital Insular de Gran Canaria between 2001 and 2018.</p></div><div><h3>Results</h3><p>During the study period, we observed an increase in the number of patients referred to long-term care centres, from 9.14% between 2001 and 2010 to 18.4% between 2011 and 2018 (<em>P</em> &lt; .01). Of 20 variables that presented a significant association with destination at discharge in the univariate study, 7 presented a significant association in the multivariate study: age (OR: 1.05; 95% CI, 1.02–1.08), living with a partner (OR: 0.26; 95% CI, 0.09−0.76), residing on another island (OR: 3.57; 95% CI, 1.32–9.63), smoking (OR: 3.44; 95% CI, 1.26–9.44), diabetes (OR: 6.51; 95% CI, 1.46–29.02), history of psychiatric disorders (OR: 3.79; 95% CI, 1.31–10.93), and scores on the Spinal Cord Independence Measure-III (SCIM-III) (OR: 0.48; 95% CI, 0.33−0.69).</p></div><div><h3>Conclusions</h3><p>Our findings identified advanced age, living on the island of Tenerife, not being married, smoking, type 2 diabetes mellitus, history of psychiatric disorders, and low SCIM-III scores as predictive factors of referral to a long-term care centre in patients with traumatic SCI in the Canary Islands.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 5","pages":"Pages 432-441"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580823000251/pdfft?md5=fc87f36773a03982b26d2a65f05c85d4&pid=1-s2.0-S2173580823000251-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9423594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel multifunctional nanoliposomes inhibit α-synuclein fibrillization, attenuate microglial activation, and silence the expression of SNCA gene","authors":"A. Jebali ,&nbsp;M. Rashidi ,&nbsp;R. Keikha ,&nbsp;K. Daliri ,&nbsp;T.F. Outeiro","doi":"10.1016/j.nrleng.2021.08.003","DOIUrl":"https://doi.org/10.1016/j.nrleng.2021.08.003","url":null,"abstract":"<div><h3>Introduction</h3><p>The aim of this study was to compare the effect of five types of PEGlated nanoliposomes (PNLs) on α-synuclein (α-syn) fibrillization, attenuation of microglial activation, and silence of the <em>SNCA</em> gene, which encodes α-syn.</p></div><div><h3>Methods</h3><p>To evaluate the inhibition of α-syn fibrillization, we used standard in vitro assay based on Thioflavin T (ThT) fluorescence. Next, to evaluate the attenuation of microglial activation, the concentration of TNF-a and IL-6 was quantified by ELISA assay in BV2 microglia cells treated with 100<!--> <!-->nM A53T α-syn and PNLs. In order to determine the silencing of the <em>SNCA</em>, real-time PCR and Western blot analysis was used. Finally, the efficacy of PNLs was confirmed in a transgenic mouse model expressing human α-syn.</p></div><div><h3>Results</h3><p>ThT assay showed both PNL1 and PNL2 significantly inhibited a-syn fibrillization. ELISA test also showed the production of TNF-a and IL-6 was significantly attenuated when microglial cells treated with PNL1 or PNL2. We also found that <em>SNCA</em> gene, at both mRNA and protein levels, was significantly silenced when BV2 microglia cells were treated with PNL1 or PNL2. Importantly, the efficacy of PNL1 and PNL2 was finally confirmed in vivo in a transgenic mouse model.</p></div><div><h3>Conclusions</h3><p>In conclusion, the novel multifunctional nanoliposomes tested in our study inhibit α-syn fibrillization, attenuate microglial activation, and silence <em>SNCA</em> gene<em>.</em> Our findings suggest the therapeutic potential of PNL1 and PNL2 for treating synucleinopathies.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 4","pages":"Pages 321-328"},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000348/pdfft?md5=a2231bf81278cf87a92e3b9bf7281d15&pid=1-s2.0-S2173580824000348-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140548455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra and inter-rater remote assessment of bradykinesia in Parkinson's disease","authors":"L.M.D. Luiz,&nbsp;I.A. Marques,&nbsp;J.P. Folador,&nbsp;A.O. Andrade","doi":"10.1016/j.nrleng.2021.08.006","DOIUrl":"https://doi.org/10.1016/j.nrleng.2021.08.006","url":null,"abstract":"<div><h3>Introduction</h3><p>Reliable assessment of individuals with Parkinson's disease (PD) is essential for providing adequate treatment. Clinical assessment is a complex and time-consuming task, especially for bradykinesia, since its evaluation can be influenced by the degree of experience of the examiner, patient collaboration and individual bias. Improvement of the clinical evaluation can be obtained by considering assessments from several professionals. However, this is only true when inter and intra-rater agreement are high. Recently, the Movement Disorder Society highlighted, during the COVID-19 pandemic, the need to develop and validate technologies for remote assessment of the motor status of people with PD. Thus, this study introduces an objective strategy for the remote evaluation of bradykinesia using multi-specialist analysis.</p></div><div><h3>Methods</h3><p>Twelve volunteers with PD participated and these were asked to execute finger tapping, hand opening/closing and pronation/supination movements. Each task was recorded and rated by fourteen PD health experts for each patient. The scores were assessed on an individual basis. Intra and inter-rater agreement and correlation were estimated.</p></div><div><h3>Results</h3><p>The results showed that agreements and correlations between experienced examiners were high with low variability. In addition, group analysis was noted as possessing the potential to solve individual inconsistency bias.</p></div><div><h3>Conclusion</h3><p>Furthermore, this study demonstrated the need for a group with prior training and experience, along with indicating the importance for the development of a clinical protocol that can use telemedicine for the evaluation of individuals with PD, as well as the inclusion of a specialized mediating group. In Addition, this research helps to the development of a valid remote assessment of bradykinesia.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 4","pages":"Pages 345-352"},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000567/pdfft?md5=803ffd7791944c3107ed558ce5ffb08a&pid=1-s2.0-S2173580824000567-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140548458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticonvulsant effects of Paeonia daurica subsp. macrophylla root extracts in pentylenetetrazol-induced seizure models in mice","authors":"E. Tahmasebi ,&nbsp;H. Monsef-Esfahani ,&nbsp;M. Vazirian ,&nbsp;P. Sharafi-Badr ,&nbsp;M. Sharifzadeh ,&nbsp;S.N. Sadati Lamardi","doi":"10.1016/j.nrleng.2021.08.004","DOIUrl":"https://doi.org/10.1016/j.nrleng.2021.08.004","url":null,"abstract":"<div><h3>Introduction</h3><p>In the present study, anticonvulsant effects of aqueous extract (AE), hydro-alcoholic crude extract (HE), and its fractions (F-CHCl₃, F-EtOAc, F-MeOH) of <em>Paeonia daurica</em> subsp. <em>macrophylla</em> (<em>P. daurica</em> ssp. <em>macrophylla</em>) root examined by using a pentylenetetrazol-induced model (PTZ) on mice.</p></div><div><h3>Methods</h3><p>HE and its fractions as well as AE, in concentrations of (100, 200 and 400<!--> <!-->mg/kg), valproate (Val) (100 and 200<!--> <!-->mg/kg), and saline (negative control) (10<!--> <!-->mg/kg) were injected intraperitoneally (i.p.) 30<!--> <!-->min before PTZ (80<!--> <!-->mg/kg, i.p.). The time taken before the onset of myoclonic convulsions (MC), MC duration, time taken before the onset of generalized tonic-clonic seizures (GTCS), the duration of GTCS, and the percentage of GTCS and mortality protection recorded. The plant's anticonvulsant mechanisms were assessed using flumazenil (5<!--> <!-->mg/kg, i.p.) before AE (100, 200, and 400<!--> <!-->mg/kg, i.p.) injection. GraphPad Prism software was used to compare the differences between various treatment groups with one-way analysis of variance (ANOVA) followed by Tukey–Krammer multiple comparison tests.</p></div><div><h3>Results</h3><p>All the plant samples except F-EtOAc significantly delayed the onset and decreased the duration of PTZ-induced MCS and GTCS, and significantly reduced the GTCS and mortality rate. Pretreatment with flumazenil diminished the significant anticonvulsant effects of AE against PTZ-induced seizures.</p></div><div><h3>Conclusions</h3><p>It can report that extract of <em>P</em>. <em>daurica</em> ssp. <em>macrophylla</em> might be a helpful guide for future studies in the treatment of epilepsy.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 4","pages":"Pages 329-339"},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S217358082400035X/pdfft?md5=3ba45cb7f228c23924ab5ab3a9963386&pid=1-s2.0-S217358082400035X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140548456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}